Biofilm formation by Stenotrophomonas maltophilia:: Modulation by quinolones, trimethoprim-sulfamethoxazole, and ceftazidime

被引:136
|
作者
Di Bonaventura, G
Spedicato, A
D'Antonio, D
Robuffo, I
Piccolomini, R
机构
[1] Univ G DAnnunzio, Ctr Sci Invecchiamento, Lab 27, I-66100 Chieti, Italy
[2] Univ G DAnnunzio, Dipartimento Sci Biomed, Lab Microbiol Clin, I-66100 Chieti, Italy
[3] Univ G DAnnunzio, Ctr Sci Invecchiamento, I-66100 Chieti, Italy
[4] CNR, Ist Trapianti Organo & Immunocitol, Sez Chieti, Chieti, Italy
[5] ASL, Serv Microbiol Clin, Dipartimento Ematol & Oncol, Osped Spirito Santo, Pescara, Italy
关键词
D O I
10.1128/AAC.48.1.151-160.2004
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
We investigated the in vitro effects of seven fluoroquinolones (ciprofloxacin, grepafloxacin, levofloxacin, moxifloxacin, norfloxacin, ofloxacin, and rufloxacin), compared to those of trimethoprim-sulfamethoxazole (SXT) and ceftazidime on total biomass and cell viability of Stenotrophomonas maltophilia biofilm. S. maltophilia attached rapidly to polystyrene, within 2 h of incubation, and then biofilm formation increased over time, reaching maximum growth at 24 h. In the presence of fluoroquinolones at one-half and one-fourth the MIC, biofilm biomass was significantly (P < 0.01) reduced to 55 to 70% and 66 to 76% of original mass, respectively. Ceftazidime and SXT did not exert any activity. Biofilm bacterial viability was significantly reduced by all antibiotics tested at one-half the MIC. At one-fourth the MIC all antibiotics, except levofloxacin, significantly reduced viability. Treatment of preformed biofilms with bactericidal concentrations (500, 100, and 50 mu g/ml) of all fluoroquinolones caused, except for norfloxacin, significant reduction of biofilm biomass to 29.5 to 78.8, 64.1 to 83.6, and 70.5 to 82.8% of original mass, respectively. SXT exerted significant activity at 500 mu g/ml only. Ceftazidime was completely inactive. Rufloxacin exhibited the highest activity on preformed biofilm viability, significantly decreasing viable counts by 0.6, 5.4, and 17.1% at 500, 100, and 50 mu g/ml, respectively. Our results show that (i) subinhibitory (one-half and one-fourth the MIC) concentrations of fluoroquinolones inhibit adherence of S. maltophilia to polystyrene and (ii) clinically achievable concentrations (50 and 100 mu g/ml) of rufloxacin are able to eradicate preformed S. maltophilia biofilm.
引用
收藏
页码:151 / 160
页数:10
相关论文
共 50 条
  • [41] Effects of Fluoroquinolones and Azithromycin on Biofilm Formation of Stenotrophomonas maltophilia
    Wang, Aihua
    Wang, Qinqin
    Kudinha, Timothy
    Xiao, Shunian
    Zhuo, Chao
    SCIENTIFIC REPORTS, 2016, 6
  • [42] Effective strategies for managing trimethoprim-sulfamethoxazole and levofloxacin-resistant Stenotrophomonas maltophilia infections: bridging the gap between scientific evidence and clinical practice
    Mokrani, David
    Luyt, Charles-Edouard
    CURRENT OPINION IN INFECTIOUS DISEASES, 2024, 37 (06) : 554 - 564
  • [43] Brevundimonas vesicularis bacteremia resistant to trimethoprim-sulfamethoxazole and ceftazidime in a tertiary hospital in southern Taiwan
    Zhang, Chun-Cheng
    Hsu, Hui-Jine
    Li, Chien-Ming
    JOURNAL OF MICROBIOLOGY IMMUNOLOGY AND INFECTION, 2012, 45 (06) : 448 - 452
  • [44] A 10-year review of risk factors, outcomes and genetic determinants of trimethoprim-sulfamethoxazole non-susceptible Stenotrophomonas maltophilia acquisition in Malaysia
    Mosiun, Sairina
    Hasan, Habsah
    Mohammad, Wan Mohd Zahiruddin Wan
    Chua, Wei Chuan
    Deris, Zakuan Zainy
    MALAYSIAN JOURNAL OF MICROBIOLOGY, 2025, 21 (01) : 90 - 101
  • [45] Trimethoprim-Sulfamethoxazole Versus Levofloxacin for Stenotrophomonas maltophilia Infections: A Retrospective Comparative Effectiveness Study of Electronic Health Records from 154 US Hospitals
    Sarzynski, Sadia H.
    Warner, Sarah
    Sun, Junfeng
    Matsouaka, Roland
    Dekker, John P.
    Babiker, Ahmed
    Li, Willy
    Lai, Yi Ling
    Danner, Robert L.
    Fowler, Vance G., Jr.
    Kadri, Sameer S.
    OPEN FORUM INFECTIOUS DISEASES, 2022, 9 (02):
  • [46] Trimethoprim/Sulfamethoxazole vs Minocycline for the Treatment of Nonurinary Monomicrobial Stenotrophomonas maltophilia Infections in Hospitalized Patients
    Hevia, Emma C.
    Wooten, Leslie
    Carr, Amy L.
    ANNALS OF PHARMACOTHERAPY, 2024, 58 (07) : 698 - 704
  • [47] Two randomized controlled trials of ceftazidime alone versus ceftazidime in combination with trimethoprim-sulfamethoxazole for the treatment of severe melioidosis
    Chierakul, W
    Anunnatsiri, S
    Short, JM
    Maharjan, B
    Mootsikapun, P
    Simpson, AJH
    Limmathurotsakul, D
    Cheng, AC
    Stepniewska, K
    Newton, PN
    Chaowagul, W
    White, NJ
    Peacock, SJ
    Day, NP
    Chetchotisakd, P
    CLINICAL INFECTIOUS DISEASES, 2005, 41 (08) : 1105 - 1113
  • [48] Evolution of Resistance against Ciprofloxacin, Tobramycin, and Trimethoprim/Sulfamethoxazole in the Environmental Opportunistic Pathogen Stenotrophomonas maltophilia
    Ochoa-Sanchez, Luz Edith
    Martinez, Jose Luis
    Gil-Gil, Teresa
    ANTIBIOTICS-BASEL, 2024, 13 (04):
  • [49] The sul1 Gene in Stenotrophomonas maltophilia With High-Level Resistance to Trimethoprim/Sulfamethoxazole
    Chung, Hae-Sun
    Kim, Kyeongmi
    Hong, Sang Sook
    Hong, Seong Geun
    Lee, Kyungwon
    Chong, Yunsop
    ANNALS OF LABORATORY MEDICINE, 2015, 35 (02) : 246 - 249
  • [50] Clinical and microbiological characteristics of patients colonized or infected by Stenotrophomonas maltophilia: is resistance to sulfamethoxazole/trimethoprim a problem?
    Mendes, Elisa Teixeira
    Garcia Paez, Jorge Isaac
    Ferraz, Juliana Rosa
    Marchi, Ana Paula
    Avelino Franca e Silva, Ivan Leonardo
    Batista, Marjorie Vieira
    Munhoz de Lima, Ana Lucia
    Rossi, Flavia
    Levin, Anna Sara
    Costa, Silvia Figueiredo
    REVISTA DO INSTITUTO DE MEDICINA TROPICAL DE SAO PAULO, 2020, 62 : e96